Repare Therapeutics Inc (OQ:RPTX)
Business Focus: Biotechnology & Medical Research
Apr 30, 2024 07:05 am ET
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, and Repare Therapeutics Inc. (“Repare”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced that the fi
Apr 30, 2024 07:05 am ET
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, and Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, today announced that the first patient has bee
Apr 26, 2024 04:05 pm ET
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the Company’s upcoming annual meeting of shareholders in June 2024. The Company also announces that Todd Foley has decided not to stand for re-election as a director of the Company following the end of his current term as a Class I director on June 17, 2024, after serving more than seven years on the Board.
Mar 21, 2024 10:00 am ET
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Repare Therapeutics Inc. (“Repare” or “the Company”) (NASDAQ: RPTX). Investors who purchased Repare securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/RPTX.
Mar 15, 2024 02:35 pm ET
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Repare Therapeutics Inc. (“Repare” or “the Company”) (NASDAQ: RPTX). Investors who purchased Repare securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/RPTX
Mar 07, 2024 04:35 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX
Pomerantz LLP is investigating claims on behalf of investors of Repare Therapeutics Inc. (“Repare” or the “Company”) (NASDAQ: RPTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The...
Mar 05, 2024 12:15 pm ET
Repare Therapeutics Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - RPTX
NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Repare Therapeutics Inc. ("Repare Therapeutics") (NASDAQ:RPTX) concerning possible violations of federal securities laws.
Feb 29, 2024 07:05 am ET
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two upcoming investor conferences. Details for the presentations are as follows.
Feb 28, 2024 04:15 pm ET
ATTENTION Repare Therapeutics Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / February 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Repare Therapeutics Inc. ("Repare Therapeutics") (NASDAQ:RPTX) concerning possible violations of federal securities laws.
Feb 28, 2024 03:54 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX
Pomerantz LLP is investigating claims on behalf of investors of Repare Therapeutics Inc. (“Repare” or the “Company”) (NASDAQ: RPTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The...
Feb 28, 2024 07:05 am ET
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2023.
Feb 27, 2024 01:30 pm ET
Repare Therapeutics Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - RPTX
NEW YORK, NY / ACCESSWIRE / February 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Repare Therapeutics Inc. ("Repare Therapeutics") (NASDAQ:RPTX) concerning possible violations of federal securities laws.
Feb 24, 2024 09:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX
NEW YORK, Feb. 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ: RPTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Feb 20, 2024 09:00 pm ET
REPARE ALERT: Bragar Eagel & Squire, P.C. is Investigating Repare Therapeutics Inc. on Behalf of Repare Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Repare Therapeutics Inc. (“Repare” or the “Company”) (NASDAQ: RPTX) on behalf of Repare stockholders. Our investigation...
Feb 20, 2024 04:02 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX
Pomerantz LLP is investigating claims on behalf of investors of Repare Therapeutics Inc. (“Repare” or the “Company”) (NASDAQ: RPTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....
Feb 16, 2024 06:28 pm ET
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)
The law firm of Kirby McInerney LLP is investigating potential claims against Repare Therapeutics Inc. (“Repare” or the “Company”) (NASDAQ:
Feb 15, 2024 05:10 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX
NEW YORK, Feb. 15, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ: RPTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Feb 15, 2024 07:05 am ET
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company’s Phase 1 LIONS (PLK4 Inhibitor in Advanced Solid Tumors) clinical trial evaluating RP-1664, a potential first-in-class, highly selective, oral polo-like kinase 4 (PLK4) inhibitor, for the monotherapy treatment of adult and adolescent
Feb 12, 2024 04:05 pm ET
Repare Therapeutics to Regain Global Rights to Camonsertib
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced today that it will regain global development and commercialization rights to camonsertib (RP-3500), a potential best-in-class oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase), following termination of its collaboration agreement with Roche.
Jan 25, 2024 07:00 am ET
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced today that, under its worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib, it has earned a $40 million milestone payment from Roche upon dosing of the first patient with camonsertib (RP-3500 or RG6526) in Roche’s TAPISTRY trial (
Jan 08, 2024 07:00 am ET
Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today provided a corporate update and highlighted key milestones anticipated in 2024.
Jan 04, 2024 04:05 pm ET
Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that it has entered into a clinical study and collaboration agreement with Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care
Dec 29, 2023 04:05 pm ET
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that its executive officers (collectively, the “Executives”) have established new Automatic Securities Disposition Plans (“ASDPs”), in accordance with applicable United States and Canadian securities legislation, including U.S. Securities and Exchange Commission (“SEC”) Rule 10b5-1 and the recommended practices set forth in the Canadian Securities A
Nov 15, 2023 07:00 am ET
Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today disclosed polo-like kinase 4 (PLK4) as the target of its RP-1664 development program and reported comprehensive preclinical data for both RP-1664 and the Company’s Polθ inhibitor, RP-3467.
Nov 09, 2023 07:00 am ET
Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023.
Nov 07, 2023 07:00 am ET
Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present the latest data from its ongoing preclinical programs, RP-1664 and RP-3467, a newly designated Polθ inhibitor, on Wednesday, November 15, 2023 at 8:00 a.m. Eastern Time.
Nov 06, 2023 07:00 am ET
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in November. Details for the fireside chats are as follows:
Oct 13, 2023 09:40 am ET
Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported positive initial data from Modules 1 and 2 of its ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib alone and in combination with camonsertib, an ATR inhibitor. The data are being presented in a plenary session titled, “New Drugs on the Horizon” at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15, 2023 in Boston, Mass.
Oct 03, 2023 07:00 am ET
Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial Phase 1 MYTHIC Modules 1 and 2 Clinical Data Presented at 35th AACR-NCI-EORTC International Conference on Molecular Targets a
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to share initial data from Module 1 and 2 of its ongoing Phase 1 MYTHIC clinical trial that will be presented in a plenary session at the upcoming AACR-NCI-EORTC conference, being held October 11-15, 2023 in Boston, MA. The data that will be presented at AACR-NCI-EORTC will be based on a later cutoff date than what is included in the abstracts, which are released on Wednesday, October 4, 2023 at 12:00 p.m. ET.
Sep 19, 2023 07:00 am ET
Repare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will present initial data from Module 1 and 2 of its ongoing Phase 1 MYTHIC clinical trial in a plenary session at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15, 2023 in Boston, MA. In addition to this presentation, the Company will present multiple posters at the conference highlighting preclinical and clinical developments, including data from Module 4 of its Phase 1/2 TRESR c
Sep 06, 2023 07:00 am ET
Repare Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023, at 11:30 a.m. Eastern Time in New York, NY.
Aug 09, 2023 04:05 pm ET
Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2023.
Jun 08, 2023 07:00 am ET
Repare Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time in Dana Point, California.
Jun 07, 2023 04:05 pm ET
Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported initial proof of concept monotherapy data from its Phase 1 MYTHIC clinical trial evaluating lunresertib (RP-6306), a first-in-class, oral PKMYT1 inhibitor in molecularly selected advanced solid tumors.
Jun 06, 2023 07:00 am ET
Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that data from the ongoing Phase 1/2 TRESR clinical trial evaluating camonsertib (RP-3500/RG6526, partnered with Roche), a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase), were published in Nature Medicine.
Jun 02, 2023 07:00 am ET
Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present initial monotherapy data from its Phase 1 MYTHIC clinical trial evaluating RP-6306, as well as to provide early insights on ongoing combination trials, on Wednesday, June 7, 2023 at 4:30 p.m. Eastern Time. RP-6306 is a first-in-class, oral PKMYT1 (Protein Kinase Membrane-associated tyrosine- and threonine- specific cdc-2 inhibitory kinase) synthetic lethal inhibitor in clinical development for the tr
May 22, 2023 07:00 am ET
Repare Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Repare Therapeutics Inc., (Nasdaq: RPTX), (“Repare”, or “the Company”), a leading clinical-stage precision oncology company, today announced that, in connection with the appointment of Daniel Belanger as the Company’s EVP, Human Resources, the Company granted Mr. Belanger an inducement stock option to purchase an aggregate of 240,000 of the Company’s common shares. The award was approved by the Compensation Committee of the Company’s Board of Directors and was granted outside of the Company’s 2020 Equity Incentive Plan, with a grant date of May 18, 2023, as an inducement material to Mr. Belang
May 09, 2023 04:05 pm ET
Repare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2023.
Apr 28, 2023 04:05 pm ET
Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Susan Molineaux, Ph.D., to its Board of Directors, effective as of the date of the Company’s upcoming annual meeting of shareholders in June 2023. Concurrent with Dr. Molineaux’s appointment as of the date of the annual meeting, Jerel Davis, Ph.D., Managing Director at Versant Ventures and a founding member of Repare’s Board of Directors, will step down from the Board.
Apr 18, 2023 10:15 am ET
Repare Therapeutics Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors at the 2023 AACR Annual Meeting
The data involving novel combinations of low doses of camonsertib and three different PARPis are featured today at the 2023 AACR Annual Meeting in a clinical plenary session titled, “Safety and efficacy of three PARP inhibitors (PARPi) combined with the ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in patients (pts) with solid tumors harboring DNA damage response (DDR) alterations” (abstract presentation number CT018). This study population comprised patients with a broad range of historically difficult to treat tumors, including patients with platinum-resistant t
Mar 14, 2023 04:58 pm ET
Repare Therapeutics Announces Plenary Oral Presentation at the 2023 AACR Annual Meeting on Camonsertib and Additional Data Presentations on RP-6306
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the data from the Phase I/II trials evaluating camonsertib (RP-3500/RG6526, partnered with Roche) in combination with three poly (ADP-ribose) polymerase inhibitors (PARPi) has been selected for the clinical plenary session at the 2023 AACR Annual Meeting, held April 14-19, 2023, in Orlando, Florida. An AACR assigned discussant of the presentation will interpret the data in this plenary session. Two poster presentations for RP-6306, a first-in-class, oral PKM
Feb 28, 2023 04:05 pm ET
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2022.
Feb 20, 2023 04:21 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repare Therapeutics Inc. - RPTX
Pomerantz LLP is investigating claims on behalf of investors of Repare Therapeutics Inc. (“Repare” or the “Company”) (NASDAQ: RPTX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Feb 14, 2023 08:28 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repare Therapeutics Inc. - RPTX
Pomerantz LLP is investigating claims on behalf of investors of Repare Therapeutics Inc. (“Repare” or the “Company”) (NASDAQ: RPTX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Feb 13, 2023 08:20 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repare Therapeutics Inc. - RPTX
NEW YORK, Feb. 13, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ: RPTX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Feb 08, 2023 11:26 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Repare Therapeutics Inc. (RPTX) Investigation
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Repare Therapeutics Inc. (“Repare” or the “Company”) (NASDAQ: RPTX). Investors who purchased Repare securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bga
Feb 02, 2023 07:00 am ET
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in February and March. Details for the fireside chats are as follows:
Jan 19, 2023 07:00 am ET
Repare Therapeutics Receives $1.5 Million (¥200 million) Payment from Ono Pharmaceuticals
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that the Company has received an approximately $1.5 million (¥200 million) research service payment from Ono Pharmaceutical Co., Ltd. (“Ono”). The payment reflects achievement of a specified research trigger, under the companies’ 2019 Strategic Partnership Agreement (“Ono Agreement”). Under the terms of the Ono Agreement, Repare is primarily responsible for carrying out research activities for its Polθ program, now known as RP-2119, until the first submissio
Dec 19, 2022 07:00 am ET
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that each of its President and Chief Executive Officer, Lloyd M. Segal, Executive Vice President and Chief Financial Officer, Steve Forte, Executive Vice President and Chief Medical Officer, Maria Koehler, Executive Vice President and Chief Scientific Officer, Michael Zinda, Executive Vice President and Chief Business Officer, Kim Seth, Executive Vi
Nov 09, 2022 04:05 pm ET
Repare Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
“Our focus in the third quarter has remained on execution of our pipeline of programs including RP-6306, our first-in-class, oral PKMYT1 inhibitor currently being evaluated in the Phase 1 MYTHIC, MAGNETIC, and MINOTAUR studies. We look forward to reporting data for RP-6306 in the first half of 2023 as we continue to execute on this novel program,” said Lloyd M. Segal, President and Chief Executive Officer of Repare. “Based on promising preclinical data released at the 34th EORTC-NCI-AACR Symposium in October 2022, Repare is working with clinical investigators to initiate clinical testing of a
Nov 07, 2022 07:00 am ET
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in November. Details for the fireside chats are as follows:
Sep 07, 2022 07:00 am ET
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in September. Details for the fireside chats are as follows:
Aug 04, 2022 04:05 pm ET
Repare Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2022.
Jun 07, 2022 07:00 am ET
Repare Therapeutics to Participate at the Goldman Sachs 43rd Annual Global Healthcare Conference
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022 at 03:20 p.m. Pacific Time/ 6:20 p.m. Eastern Time in Rancho Palos Verdes, CA.
Jun 01, 2022 04:05 pm ET
Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib (also known as RP-3500), a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of tumors with specific synthetic-lethal genomic alterations including those in the ATM gene (Ataxia-Telangiectasia mutated kinase). Under the collaboration, Roche wil
May 09, 2022 07:00 am ET
Repare Therapeutics to Participate at the 2022 Guggenheim Synthetic Lethality Day
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the virtual 2022 Guggenheim Synthetic Lethality Day on Monday, May 16, 2022 at 9:00 a.m. Eastern Time.
May 05, 2022 04:05 pm ET
Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2022.
Apr 20, 2022 11:00 am ET
Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 Amplification
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that preclinical data demonstrating inhibition of CCNE1-amplified tumor growth in vivo by selective inhibition of PKMYT1 using RP-6306, a first-in-class small molecule candidate targeting PKMYT1, were published in Nature. SNIPRx®, Repare’s proprietary, genome-wide, CRISPR-based screening approach, was used to uncover CCNE1 amplification as synthetic lethal to PKMYT1 inhibition.
Apr 11, 2022 04:05 pm ET
Repare Therapeutics Presents Updated Clinical Data from the Ongoing Phase 1/2 TRESR Study of RP-3500 Monotherapy in Solid Tumors at the 2022 AACR Annual Meeting
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today presented updated data from its ongoing Phase 1/2 TRESR (Treatment Enabled by SNIPRx) clinical trial of RP-3500, a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of solid tumors with specific synthetic-lethal genomic alterations including those in the ATM gene (Ataxia-Telangiectasia mutated kinase) at the 2022 AACR Annual Meeting.
Apr 08, 2022 01:00 pm ET
Repare Therapeutics to Present New Clinical and Preclinical Data at the 2022 AACR Annual Meeting
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it has been selected for an oral presentation of clinical data from its ongoing Phase 1/2 TRESR (Treatment Enabled by SNIPRx) trial of RP-3500, a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase), as well as two additional poster presentations at the upcoming 2022 AACR Annual Meeting held in New Orleans on April 8-13, 2022.
Mar 08, 2022 04:30 pm ET
Repare Therapeutics to Present Comprehensive Phase 1 Monotherapy Data From the Phase 1/2 TRESR RP-3500 Clinical Trial and SNiPDx Panel at the 2022 AACR Annual Meeting
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced it has been selected for an oral presentation of clinical data from its ongoing Phase 1/2 TRESR trial of RP-3500 and a poster presentation of initial discovery and validation data of the novel Synthetic Lethal Interactions for Precision Diagnostics (SNiPDx) panel to understand allelic status of STEP2 genes at the upcoming 2022 AACR Annual Meeting, b
Mar 07, 2022 07:00 am ET
Repare Therapeutics Presents RP-3500 Dose Selection Phase 1 Monotherapy Safety Data from the Phase 1/2 TRESR Clinical Trial at the 2022 ESMO Targeted Anticancer Therapies Congress
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the presentation of monotherapy dose selection and safety data from its Phase 1/2 TRESR (Treatment Enabled by SNIPRx) clinical trial of RP-3500 at the 2022 ESMO Targeted Anticancer Therapies (TAT) Congress. RP-3500 is a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) in development fo
Mar 01, 2022 04:15 pm ET
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2021.
Feb 03, 2022 07:00 am ET
Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in two virtual investor conferences in February. Details are as follows:
Jan 07, 2022 08:34 am ET
Repare Therapeutics Provides Corporate Update and Highlights Key Milestones Anticipated in 2022
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today provided a corporate update and highlighted key milestones anticipated in 2022.
Jan 05, 2022 07:00 am ET
Repare Therapeutics Expands Executive Leadership Team with the Appointment of Philip Herman as EVP Commercial & New Product Development
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Philip Herman as its EVP Commercial & New Product Development.
Jan 03, 2022 04:05 pm ET
Repare Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that Lloyd M. Segal, President and Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 3:45 p.m. Eastern Time.
Dec 21, 2021 07:00 am ET
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to discover and develop novel therapeutics, today announced the first patient has been dosed in the Company’s Phase 1 clinical trial of RP-6306, a first-in-class small molecule candidate targeting PKMYT1, in combination with gemcitabine for the treatment of molecularly selected advanced solid tumors (NCT05147272) (the “MAGNETIC” trial).
Dec 15, 2021 06:17 pm ET
Repare Therapeutics Insiders Establish New and Modified Automatic Securities Disposition Plans
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that each of its: President and Chief Executive Officer, Lloyd Segal; Executive Vice President and Chief Financial Officer, Steve Forte; Executive Vice-President and Chief Scientific Officer, Michael Zinda; Executive Vice-President and Chief Medical Officer, Maria Kohler; Executive Vice-President Discovery, Cameron Black; and Executive Vice Presiden
Nov 15, 2021 07:00 am ET
Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in two virtual investor conferences in November. Details are as follows:
Nov 10, 2021 07:00 am ET
Repare Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the third quarter ended September 30, 2021.
Nov 02, 2021 05:01 pm ET
Repare Therapeutics Announces Closing of Upsized Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the closing on November 1, 2021 of its upsized underwritten public offering of 4,600,000 common shares at a public offering price of $22.00 per share, which included the exercise in full by the underwriters of their option to purchase up to 600,000 additional shares. All common shares were sold by Repare. The total gross proceeds for the offering were approximately $101.2 million, before ded
Oct 27, 2021 08:59 pm ET
Repare Therapeutics Announces Pricing of Upsized Offering of Common Shares
Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the pricing of an upsized underwritten public offering of 4,000,000 of its common shares at a public offering price of $22.00 per share, for total gross proceeds of $88.0 million, before deducting underwriting commissions and offering expenses payable by Repare. All of the common shares are being offered by Repare. The offering is expected to close on November 1, 2021, subject to customary c
Oct 27, 2021 04:01 pm ET
Repare Therapeutics Announces Proposed Public Offering of Common Shares
Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the commencement of a proposed underwritten public offering of $75.0 million of its common shares. All common shares to be sold in the proposed offering will be sold by Repare. Repare also intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of its common shares at the public offering price, less underwriting commissions. The offering is subject to
Oct 18, 2021 07:00 am ET
Repare Therapeutics to Participate at the H.C. Wainwright 2nd Annual Precision Oncology Conference
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the H.C. Wainwright 2nd Annual Precision Oncology Conference on Wednesday, October 20, 2021 at 12:30 p.m. Eastern Time.
Oct 08, 2021 03:10 pm ET
Repare Therapeutics Presents Preliminary Phase 1 Monotherapy Clinical Data from the Ongoing First-in-Human Phase 1/2 TRESR Study of RP-3500 in Solid Tumors at AACR-NCI-EORTC International Conference o
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the presentation of preliminary Phase 1 monotherapy clinical data from its Phase 1/2 TRESR (Treatment Enabled by SNIPRx) clinical trial of RP-3500, a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of solid tumors with specific synthetic-lethal genomic alterations including those in the ATM gene (ataxia teleangectasia mutated kinase), at the AACR-NCI-EORTC Virtual Internation
Oct 07, 2021 05:08 pm ET
Repare Therapeutics Issues Statement Regarding Inadvertent Issuance of Phase 1/2 TRESR RP-3500 Clinical Trial Abstract by the AACR-NCI-EORTC Virtual International Conference
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today issued the following statement concerning the inadvertent issuance of an abstract by the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics (“ANE Conference”) concerning an upcoming oral presentation of initial monotherapy clinical data from its ongoing Phase 1/2 clinical trial of RP-3500:
Sep 30, 2021 04:30 pm ET
Repare Therapeutics to Present Initial Data from the Phase 1/2 TRESR RP-3500 Clinical Trial at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that it has been selected for an oral presentation of initial monotherapy clinical data from its ongoing Phase 1/2 clinical trial of RP-3500 and a poster presentation of preclinical data for RP-3500 at the upcoming AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, being held October 7-10, 2021. In addition, the Company will be hosting a Virtual Investor Webcast Event on Friday, October 8, 2021 at 5:00 p.m. ET.
Sep 07, 2021 07:00 am ET
Repare Therapeutics Appoints Thomas Civik to Its Board and as New Chairman
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Thomas Civik to its Board of Directors and as its Chairman. He replaces Jerel Davis, Ph.D., Managing Director at Versant Ventures, who will remain a member of the Company’s Board.
Sep 02, 2021 07:00 am ET
Repare Therapeutics to Participate at the 19th Annual Morgan Stanley Virtual Global Healthcare Conference
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in a fireside chat at the 19th Annual Morgan Stanley Virtual Global Healthcare Conference on Thursday, September 9 at 2:45 p.m. Eastern Time.
Aug 12, 2021 04:05 pm ET
Repare Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the second quarter ended June 30, 2021.
Jun 02, 2021 07:00 am ET
Repare Therapeutics to Participate at the 42nd Annual Goldman Sachs Virtual Global Healthcare Conference
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq:RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in a fireside chat at the 42nd Annual Goldman Sachs Virtual Global Healthcare Conference on Wednesday, June 9 at 3:50 p.m. Eastern Time.
May 13, 2021 04:45 pm ET
Repare Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the first quarter ended March 31, 2021.
May 03, 2021 07:00 am ET
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality (SL) approach to the discovery and development of novel therapeutics, today announced the first patient has been dosed in the Company’s Phase 1 clinical trial of RP-6306, a first-in-class small molecule product candidate targeting PKMYT1, which is a novel target that Repare discovered to be synthetic lethal with CCNE1 amplification and other genomic mutations to treat CCNE1-amplified, FBXW7-altered and other PKMYT1 inhibitor-sen
Apr 13, 2021 07:00 am ET
Repare Therapeutics to Present at the 2021 Bloom Burton & Co. Virtual Healthcare Investor Conference
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will present at the 2021 Bloom Burton & Co. Virtual Healthcare Investor Conference on Tuesday, April 20 at 9:30 a.m. ET.
Apr 08, 2021 11:05 am ET
Repare Therapeutics to Highlight Program Progress for RP-6306 at Today’s Virtual Investor Day Event
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, will host a virtual Investor Day webcast today from 10:30 a.m. – 12:00 p.m. ET, highlighting the progress of its proprietary RP-6306 program for tumors with genetic alterations characterized by CCNE1 amplification. The Company expects to initiate a Phase 1 clinical trial of RP-6306 in the second quarter of 2021.
Mar 30, 2021 04:05 pm ET
Repare Therapeutics to Introduce RP-6306, a Potent and Specific Inhibitor of a Novel Target, at Virtual Investor Day on April 8
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced it will host a virtual Investor Day on Thursday, April 8, 2021, from 10:30 a.m. to 12:00 p.m. Eastern Time. Repare Therapeutics’ executive management team will be joined by two distinguished physicians:
Mar 29, 2021 04:05 pm ET
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that each of its Executive Vice President and Chief Financial Officer, Steve Forte and its Executive Vice President and Chief Medical Officer, Maria Koehler (collectively, the “Executives”), have established Automatic Securities Disposition Plans (“ASDPs”) in accordance with applicable United States and Canadian securities legislation, including U.S
Mar 04, 2021 04:05 pm ET
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2020.
Feb 23, 2021 07:00 am ET
Repare Therapeutics Announces March 2021 Virtual Investor Conference Participation
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team are scheduled to participate in three virtual investor conferences in March. Details are as follows:
Jan 05, 2021 08:30 am ET
2020 Canadian IPO mixed results - number (77) down, amount ($5.55B) up driven by PE-backed IPOs
TORONTO, Jan. 5, 2021 /CNW/ - While the US initial public offering (IPO) and special purpose acquisition corporation (SPAC) market experienced an unprecedent boom in 2020, Canadian IPO market continued to struggle with mixed results.
Jan 04, 2021 07:00 am ET
Repare Therapeutics to Present at Virtual Investor Conferences in January
Repare Therapeutics, Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that Lloyd M. Segal, President and Chief Executive Officer, will present at two upcoming virtual investor conferences:
Dec 31, 2020 04:09 pm ET
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that each of its President and Chief Executive Officer Lloyd Segal, Executive Vice President, Chief Scientific Officer Michael Zinda, Executive Vice President, Discovery Cameron Black, and Executive Vice President, Head of Business & Corporate Development Kim Seth (collectively, the “Executives”), as well as certain other insiders of the Company (th
Dec 17, 2020 04:05 pm ET
Repare Therapeutics Added to the NASDAQ Biotechnology Index
Repare Therapeutics, Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: ^NBI). Repare’s addition to the NBI will become effective prior to market open on Monday, December 21, 2020.
Nov 23, 2020 07:00 am ET
Repare Therapeutics to Participate at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that Lloyd M. Segal, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held November 30 – December 3, 2020.
Nov 11, 2020 04:05 pm ET
Repare Therapeutics Reports Third Quarter 2020 Financial Results and Operational Highlights
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the third quarter ended September 30, 2020, as well as recent business highlights.
Sep 09, 2020 07:00 am ET
Repare Therapeutics to Participate at Morgan Stanley Annual Global Healthcare Conference
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that Lloyd M. Segal, President and Chief Executive Officer, will participate in a virtual fireside chat at the Morgan Stanley Annual Global Healthcare Conference on Tuesday, September 15 at 10:15 a.m. ET.
Aug 13, 2020 04:05 pm ET
Repare Therapeutics Reports Second Quarter 2020 Financial Results and Operational Highlights
Repare Therapeutics Inc. (“Repare”) (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the second quarter ended June 30, 2020, as well as recent operational highlights.
Jul 29, 2020 06:00 am ET
Repare Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Trial of RP-3500
“The TRESR (Treatment Enabled by SNIPRx) study of RP-3500 as a monotherapy or in combination with talazoparib is a promising targeted approach for a range of difficult-to-treat cancers in patients with tumors harboring genetic alterations we have identified and we believe could predict response,” said Lloyd M. Segal, President and Chief Executive Officer of Repare. “The RP-3500 development plan reflects our strategy to develop differentiated oncology treatments in highly targeted tumors.”
Jun 23, 2020 04:05 pm ET
Repare Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the closing of its previously announced upsized initial public offering of 12,650,000 of its common shares, including the exercise in full of the underwriters’ option to purchase up to an additional 1,650,000 common shares, at a public offering price of $20.00 per share. The gross proceeds to Repare, before deducting underwriting commissions and offering expenses, were $253.0 million. All of
Jun 18, 2020 09:56 pm ET
Repare Therapeutics Announces Pricing of Upsized Initial Public Offering
Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by our proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the pricing of its upsized initial public offering of 11,000,000 of its common shares at a public offering price of $20.00 per share. The gross proceeds to Repare, before deducting underwriting commissions and offering expenses, are expected to be approximately $220.0 million. All of the common shares are being offered by Repare. In addition, Repare has granted the underwriters a 30-day opti
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.